Global Information
회사소개 | 문의 | 비교리스트

항우울제 시장 : 세계 산업 동향, 점유율, 규모, 성장률, 기회, 예측(2021-2026년)

Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

리서치사 IMARC Services Private Limited
발행일 2021년 05월 상품코드 1007184
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
가격
US $ 2,299 ₩ 3,265,000 PDF (Single User License)
US $ 3,399 ₩ 4,828,000 PDF (5 User License)
US $ 4,499 ₩ 6,391,000 PDF (Corporate License)


항우울제 시장 : 세계 산업 동향, 점유율, 규모, 성장률, 기회, 예측(2021-2026년) Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 항우울제 시장 규모는 2020년에 127억 달러에 달했습니다. 우울증은 긍정적인 감정의 결여, 지속적인 우울한 기분 및 다수의 인지적, 신체적, 행동적, 감정적인 증상을 특징으로 하는 정신장애입니다. 증상을 식별하고, 환자의 병력을 확인하는 것에 의해 진단됩니다. 다음으로 뇌내 세로토닌 등 신경전달물질의 기능의 균형을 잡고, 환자의 기분 및 감정을 제어하는 항우울제를 사용하여 치료됩니다. 이 치료제는 불안, 계절성우울증, 기분변조의 징후를 완화시키는데 도움이 됩니다.

세계보건기구(WHO)에 따르면 우울증은 장애의 주요 원인의 하나이며, 전 세계에서 2억 6,400만 명 이상에 영향을 미치고 있습니다. 사회 불안 및 우울증 등 정신장애의 만연의 증가는 항우울제 시장의 성장을 촉진하는 주요 요인의 하나입니다. 이것과는 별개로 신종 코로나바이러스 감염증(COVID-19)의 증례 급증에 수반하여 사람들에게는 상당한 정도의 공포, 걱정, 우려가 있습니다. 또한 각국의 정부가 완전한 봉쇄를 부과하고 사회적 거리두기 기준의 채택을 촉진하고 있으므로 인구의 상당한 부분의 일상생활이 변화하며, 그것이 개인의 정신적 건강에 악영향을 미치고 있습니다. 이 동향은 항우울제의 판매를 촉진하는 또 하나의 주요 성장 유발 요인으로 부상하고 있습니다. 또한 최소한의 부작용과 장기적인 결과를 얻을 수 있는 항우울제를 개발하기 위한 새로운 기술의 출현은 신약 수용의 증가와 함께 향후 수년간 시장 성장을 지원할 것으로 예상되고 있습니다. 세계의 항우울제 시장은 2021-2026년의 예측 기간 중 약 3%의 CAGR로 성장할 것으로 예상되고 있습니다.

세계의 항우울제 시장에 대해 조사했으며, 업계 동향, 시장 예측, 약물 클래스·장애 유형·약 유형·유통 채널·지역별 시장 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서문

제2장 범위와 조사 방법

제3장 개요

제4장 서론

제5장 세계의 항우울제 시장

  • 시장 개요
  • 시장 실적
  • COVID-19의 영향
  • 약물 클래스별 시장 세분화
  • 장애 유형별 시장 세분화
  • 약 유형별 시장 세분화
  • 유통 채널별 시장 세분화
  • 지역별 시장 세분화

제6장 약물 클래스별 시장 세분화

  • 비정형항정신병약
  • 세로토닌-노르에피네프린 재수용 저해제(SNRI)
  • 선택적 세로토닌 재수용 저해제(SSRI)
  • 중추신경계(CNS) 각성제
  • 삼환계 항우울제
  • 모노아민 옥시다아제 저해제
  • 기타

제7장 장애 유형별 시장 세분화

  • 주요우울장애
  • 강박장애
  • 범불안장애
  • 공황장애
  • 기타

제8장 약 유형별 시장 세분화

  • 제네릭 의약품
  • 브랜드약

제9장 유통 채널별 시장 세분화

  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 기타

제10장 지역별 시장 세분화

  • 북미
  • 유럽
  • 아시아태평양
  • 중동·아프리카
  • 라틴아메리카

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter의 산업 분석

제14장 가격 분석

제15장 경쟁 구도

  • 시장 구조
  • 주요 기업
  • 주요 기업의 개요
    • Otsuka Pharmaceutical
    • Pfizer
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis
    • Bristol-Myers Squibb
    • GlaxoSmithKline
    • Takeda Pharmaceutical Company
    • Allergan
    • Johnson & Johnson
    • Zhejiang NHU Company Ltd
    • Sebela Pharmaceuticals
KSA 21.06.29

List of Figures

  • Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Depression Drugs Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2020
  • Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2020
  • Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2020
  • Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2020
  • Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2020
  • Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 9: Global: Depression Drugs Industry: SWOT Analysis
  • Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
  • Figure 11: Global: Depression Drugs Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulant) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulant) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2015 & 2020
  • Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2021-2026
  • Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million US$), 2015 & 2020
  • Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2021-2026
  • Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million US$), 2015 & 2020
  • Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2021-2026
  • Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million US$), 2015 & 2020
  • Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2021-2026
  • Figure 48: North America: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 50: Europe: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026

List of Tables

  • Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
  • Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million US$), 2021-2026
  • Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
  • Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 7: Global: Depression Drugs Market Structure
  • Table 8: Global: Depression Drugs Market: Key Players

The global depression drugs market reached a value of US$ 12.7 Billion in 2020. Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Apart from this, with the surge in the cases of the coronavirus disease (COVID-19), there is a considerable degree of fear, worry and concern in the population. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years. Looking forward, the global depression drugs market is expected to grow at a CAGR of around 3% during the forecast period (2021-2026).

IMARC Group's latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global depression drugs market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug class, disorder type, drug type, and distribution channel.

Report Coverage:

  • Historical, Current and Future Market Trends

Market Breakup by Drug Class:

  • Atypical Antipsychotics
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Central Nervous System (CNS) Stimulants
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Others

Market Breakup by Disorder Type:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

Market Breakup by Drug Type:

  • Generic Drugs
  • Branded Drugs

Market Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Competitive Landscape:

  • The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Depression Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Class
  • 5.5 Market Breakup by Disorder Type
  • 5.6 Market Breakup by Drug Type
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Atypical Antipsychotics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Central Nervous System (CNS) Stimulants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tricyclic Antidepressants
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Monoamine Oxidase Inhibitors
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disorder Type

  • 7.1 Major Depressive Disorder
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Obsessive-Compulsive Disorder
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Generalized Anxiety Disorder
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panic Disorder
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Generic Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Branded Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Otsuka Pharmaceutical
    • 15.3.2 Pfizer
    • 15.3.3 Eli Lilly and Company
    • 15.3.4 AstraZeneca
    • 15.3.5 Novartis
    • 15.3.6 Bristol-Myers Squibb
    • 15.3.7 GlaxoSmithKline
    • 15.3.8 Takeda Pharmaceutical Company
    • 15.3.9 Allergan
    • 15.3.10 Johnson & Johnson
    • 15.3.11 Zhejiang NHU Company Ltd
    • 15.3.12 Sebela Pharmaceuticals
Back to Top
전화 문의
F A Q